Eirini Papapetrou, MD, PhD
Assistant Professor, Division of Hematology, Dept of Medicine
Our group uses human pluripotent stem cells, particularly induced pluripotent stem (iPS) cells, with the goals of studying normal and abnormal hematopoiesis and developing new technologies towards the use of iPS cells in cell therapies. We have developed new tools to generate transgene-free human iPS cells and to genetically engineer them in safe harbor sites in the human genome. We are harnessing these technologies to better understand the genetic basis of myelodysplastic syndromes and to advance iPS cell research towards translation to the clinic. We are using reprogramming of patient-derived hematopoietic cells and genetic engineering of normal human pluripotent stem cells to develop new models of dysplastic hematopoiesis. We are also developing new approaches to generate safer genetically modified iPS cells for cell therapies.